SCHEMBL6995871

SCHEMBL6995871

CC(=O)Oc1c(-c2ccccc2)[nH]c2ccccc12

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TUBB4A P04350 1/20 0.53
TUBB P07437 1/20 0.53
TUBA3C P0DPH7 1/20 0.53
TUBA1B P68363 1/20 0.53
TUBA4A P68366 1/20 0.53
TUBB4B P68371 1/20 0.53
TUBB3 Q13509 1/20 0.53
TUBB2A Q13885 1/20 0.53
TUBB8 Q3ZCM7 1/20 0.53
TUBA3E Q6PEY2 1/20 0.53
TUBA1A Q71U36 1/20 0.53
TUBA1C Q9BQE3 1/20 0.53
TUBB6 Q9BUF5 1/20 0.53
TUBB2B Q9BVA1 1/20 0.53
TUBB1 Q9H4B7 1/20 0.53
ESR1 P03372 3/20 0.51
ESR2 Q92731 3/20 0.51
GSK3B P49841 2/20 0.51
ADK P55263 2/20 0.51
KMT2A Q03164 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13689695 0.90 USP2 (0.53) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL28974916 0.88 TUBB4A (0.57) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL27905704 0.86 GAA (0.58) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL6471859 0.81 GSK3B (0.59) GSK3BADKKMT2AUSP2HPGD
SCHEMBL2348532 0.81 ALDH1A1 (0.48) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL5191713 0.80 MEN1 (0.48) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL11667064 0.80 GSK3B (0.54) GSK3BADKKMT2AUSP2HPGD
SCHEMBL27803171 0.80 NR4A2 (0.55) GSK3BADKKMT2AUSP2HPGD
SCHEMBL30681851 0.79 SLC22A6 (0.53) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL8705925 0.79 SLC22A6 (0.53) TUBB4ATUBBTUBA3CTUBA1BTUBA4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117586235-A Chimeric molecules for enhancing mitochondrial autophagy and uses thereof 广东省人民医院 2024-02-23 CN disclosed
US-10654838-B2 Aminopyridine compounds useful as inhibitors of protein prenylation INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 2020-05-19 US disclosed
EP-3204380-B1 NOVEL AMINOPYRIDINE COMPOUNDS USEFUL AS INHIBITORS OF PROTEIN PRENYLATION INST NAT SANTE RECH MED (FR) 2019-08-07 EP disclosed
US-20170305892-A1 NOVEL AMINOPYRIDINE COMPOUNDS USEFUL AS INHIBITORS OF PROTEIN PRENYLATION INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 2017-10-26 US disclosed
EP-0859004-B1 Piperidine derivatives having anxiolytic effect LUNDBECK & CO AS H (DK) 2003-05-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170305892-A1 NOVEL AMINOPYRIDINE COMPOUNDS USEFUL AS INHIBITORS OF PROTEIN PRENYLATION RCE1, PTAR1, CDK2AP1 TUBB4A 1455/4885TUBB 2410/4885TUBA3C 2528/4885
US-10654838-B2 Aminopyridine compounds useful as inhibitors of protein prenylation RCE1, PTAR1, CDK2AP1 TUBB4A 1505/4885TUBB 2381/4885TUBA3C 2587/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.